- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 214
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
- Interventions
- Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 153
- States / cities
- Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- ThermoDox, Dummy infusion
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
- Conditions
- Sarcoma
- Interventions
- Bevacizumab, Doxorubicin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ewing's Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Dexrazoxane, ImmTher
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Kaposi
- Interventions
- Liposomal Doxorubicin, Bevacizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Bortezomib, Doxorubicin hydrochloride (HCl), PEG-Asparaginase, Vincristine sulfate, Dexamethasone, Cytarabine, Methotrexate
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Vorinostat, Bortezomib, pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Leiomyosarcoma
- Interventions
- Ontorpacept (TTI-621), Doxorubicin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Santa Monica, California • Jacksonville, Florida • Tampa, Florida + 16 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
- Drug
- Lead sponsor
- DynamiCure Biotechnology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- T138067 intravenous, doxorubicin intravenous
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Miami, Florida + 4 more
- Conditions
- Breast Cancer
- Interventions
- CDX-011, "Investigator's Choice" chemotherapy
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 19 more
- Conditions
- Sarcoma, Nausea, Vomiting
- Interventions
- Palonosetron - Single Dose, Palonosetron - Triple Dose, Adriamycin, Ifosfamide chemotherapy (AI), Zinecard, Mesna, Vincristine, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors - Phase 1 Population
- Interventions
- GPX-150 for Injection
- Drug
- Lead sponsor
- Gem Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Olaratumab, Doxorubicin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Ovarian Neoplasms
- Interventions
- AZD2281, Liposomal Doxorubicin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Olaratumab, doxorubicin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Radiotherapy (RT)
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 104
- States / cities
- Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
- Conditions
- Solid Tumors
- Interventions
- Doxil, Gemcitabine, Velcade
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Interventions
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 927 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 22
- States / cities
- Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more